IMRA News and Press, IMARA Inc. From 12/14/21

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 activation of Nrf2 increases HbF and F-cells, reduces VOCs and reduces markers of a...

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on track for interim analysis of VOC rates in first quarter of 2022 BOSTON, Nov....

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In order to find penny stocks that have a strong likelihood of booking profits within the next six weeks, investors are going to have to accept an extra measure of risk. That’s because there’s inherent risk i...

Imara (NASDAQ:IMRA) announces data from a pre-specified interim analysis from its Forte Phase 2b clinical trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia. Shares advance 4.5% premarket. “We are encouraged by the positive trend for...

Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clin...

IMARA Inc. (IMRA) Q3 2021 Results Conference Call November 09, 2021 08:30 AM ET Company Participants Rahul Ballal - President, CEO Mike Gray - CFO, COO Ken Attie - SVP, CMO Conference Call Participants Carly Kenselaar - Citi Costa Sean - Morgan Stanley Presentation Operator Good day, and than...

Imara (NASDAQ:IMRA): Q3 GAAP EPS of -$0.55 beats by $0.05. Cash, cash equivalents and investments of $102.84M. Press Release The company currently expects FY2021 research and development expenses to range between $40M-$45M and general and administrative expenses between $12M-$13M. The co...

Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 activator shown to reactivat...

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara’s new Vice President of Clinical Development BO...